The Tinea Pedis (Athlete Foot) drugs in development market research report provides comprehensive information on the therapeutics under development for Tinea Pedis (Athlete Foot), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tinea Pedis (Athlete Foot). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tinea Pedis (Athlete Foot) and features dormant and discontinued products.

GlobalData tracks six drugs in development for Tinea Pedis (Athlete Foot) by five companies/universities/institutes. The top development phase for Tinea Pedis (Athlete Foot) is phase ii with five drugs in that stage. The Tinea Pedis (Athlete Foot) pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Tinea Pedis (Athlete Foot) pipeline products market are: DermBiont, Eisai and China Medical System.

The key targets in the Tinea Pedis (Athlete Foot) pipeline products market include Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17), and Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154).

The key mechanisms of action in the Tinea Pedis (Athlete Foot) pipeline product include Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17) Inhibitor with one drug in Phase II. The Tinea Pedis (Athlete Foot) pipeline products include three routes of administration with the top ROA being Topical and two key molecule types in the Tinea Pedis (Athlete Foot) pipeline products market including Small Molecule, and Biologic.

Tinea Pedis (Athlete Foot) overview

Athlete’s foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odor, and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines.

For a complete picture of Tinea Pedis (Athlete Foot)’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.